We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.25 | -1.43% | 17.25 | 17.00 | 17.50 | 17.50 | 17.25 | 17.50 | 127,454 | 11:00:21 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 6.07 | 15.73M |
Date | Subject | Author | Discuss |
---|---|---|---|
02/11/2017 19:08 | Bob - you are preaching to the converted. ALL LTH here know of SBTX's huge potential and most will be invested via OPTI as well as ploughing their own hard earned into it, including me. We are well versed on what is needed, we have learned much of the process via our experience with OPTI. SBTX is NOT a no brainer until the science has been proved via human trials and commercial agreements are agreed - OPTI is a no brainer. | elrico | |
02/11/2017 18:37 | SBTX is a bigger multi-bagger...more cash will be made for investors at present levels of about 10p....in a few years expect SBTX to be worth 70p or more and benefiting from the market storm from OPTI. SBTX is a NO-BRAINER share price RISER WITH SHARED OPTI MARKETING CONTACTS AND SKILLS. | bobalot | |
02/11/2017 18:09 | OPTI must be going on more and more radars as the price continues to rise. The chart looks primed to have another crack at 80p over the next few trading days. | parob | |
02/11/2017 17:38 | SBTX will come good in time however as we have see with Opti translating the science in to products and partnering with the global heavyweights doesn't happen overnight and must follow a process. Human studies and expectation of the results will begin the gradual rerate id expect. I do feel SBTX are not telling a good story currently and no one really has much of an idea of what's going on which obviously isn't enticing investors. Good buying opportunity to tuck away as has already been said. | riskybusiness1 | |
02/11/2017 17:29 | I try not to concern myself with the trading range or news expectations because like so many here im thinking of a few years down the road. I have noticed a little change in the trading cycle though. The swings are not a prominent and the drip sellers are not as obvious to me. I have no clue to charting at all so trust others when they suggest a change in direction being very likely. I just wish i had more funds. | slartybartfaster | |
02/11/2017 16:07 | #bobalot they are looking at human trials in 2018 , I think your enthusiasm is fun but "wobbles perm" calm down calm down | rathean | |
02/11/2017 15:55 | I wouldn’t be surprised if he wrote that report himself. Anyone checked the author? | shazbo | |
02/11/2017 15:48 | SkioBio is not years away from commercialising a product -- they are planning that for late next year. | bobalot | |
02/11/2017 15:43 | bobalot, please keep your ludicrous ramping to the SBTX board. I welcome measured opinion but you are so embarrassingly blatant you have no credibility. | shazbo | |
02/11/2017 15:26 | #bobalot good post but they are years off commercialisation... I suppose something to buy and hide under your mattress. | rathean | |
02/11/2017 15:06 | SBTX is making really good progress thanks to OPTI and Dr. Cath: SkinBioTherapetics' Dr Cath O'Neill named one of healthcare's top movers and shakers Share 10:21 02 Nov 2017 Dr Cath O'Neill, chief executive of SkinBioTherapetics PLC (LON:SBTX), caught up with Proactive Investors after being recognised as one of the top 50 female leaders in UK healthcare as part of BioBusiness' 2017 50 Movers and Shakers report. Dr O'Neill's been recognised for her research within the skin microbiome sector. Here are a few things she mentioned in the interview. Clinical safety trials using people will start early next year followed by a months human clinical trial in Q3 --- so safety trials are first human tests in early 2018. This is all part and parcel of the same---- two sets of human safety trials followed by a months clinical trial. Then that will be followed with Eczma trials see the video interview: THE COMPANY IS MAKING RAPID PROGRESS | bobalot | |
02/11/2017 14:36 | The deals are racking up nicely. Not long now until take off guys. | parob | |
02/11/2017 12:36 | I think you could be spot on. I have broken my investment rules and now hold the most OPTI I ever have. | rafboy | |
02/11/2017 12:22 | raf, its weird because weve mostly all been here for quite a while so this transitional phase has felt like a long time coming. hence, most of us are constantly wanting news and coverage daily. however, I genuinely feel opti are poised in the starting blocks for the next stage now and each deal that gets announced makes the case stronger. some people go on and on about earnings but lets face it they wouldn't have the chance to buy at these prices if there were clarity of earnings. this is an opportunity to buy a stock that could and should be several times higher in 18-24 months time as solid revenues come through and the growth is witnessed. that's why I think any rise could be quick, its not next years revenues im interested in, this is a whole new science and chapter in human health so the growth of take up, new deals and earnings imho will be very very fast as the science is more widely known. for now its about whether one feels happy with the commercial deals soh is agreeing for shareholder value and the quality of the partners. on both fronts I think he gets 10 out of 10 so far. add in his recruitment policy and hes added top level people. so if it takes a day, a week or a 6 more months opti's investment case just keeps getting stronger. I cant substantiate this but I really do feel this has been range bound for someone to accumulate. any decent buy and they move it up to discourage..... time will tell if im right or its wishful thinking. sm | shrewdmole | |
02/11/2017 12:05 | I am hoping for a bit of weekend press. | rafboy | |
02/11/2017 12:02 | raf, ok mate I did wonder. wonder if that 30k is a buy or a sell, either way seems some nice sized trades again. cant believe we wont or haven't got some institutional interest here with all the news and notes...... sm | shrewdmole | |
02/11/2017 11:54 | shrewdmole, I just bought 3507 shares at 73.95p so they may be buys. Just shown up on NEX. | rafboy | |
02/11/2017 11:51 | SkinBioTherapetics' Dr Cath O'Neill named one of healthcare's top movers and shakers - | loungeact | |
02/11/2017 11:45 | guys are those last few trades sells ? if so starting to pay mid. great article and coverage like that never hurts. | shrewdmole | |
02/11/2017 11:35 | Nice find Parob. Nothing new in one sence, but it's great to see us getting more Investor exposure. Ta, John | 2350220 | |
02/11/2017 11:10 | Interesting! Optibiotix Health - Rapidly Transitioning to Commercial Phase Writen by Riccardo Lowi Published: 10:14, 02 Nov 2017 | parob | |
02/11/2017 10:19 | that chart is looking very nice indeed..... | shrewdmole | |
02/11/2017 09:59 | Yep - share price looks like it wants to rise today | jestercat2 | |
02/11/2017 09:50 | just had to pay over the ask for 20+k despite 30k being shown on the offer. wont take much to get this breakout imho. trade not showing yet. | shrewdmole | |
02/11/2017 09:30 | Hi Parob, I'm away, but from what I can see on ADVFN charts I couldn't feel more bullish;¬) ATB Martin | marnewton |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions